Immunotropic therapy using Ruzam in treating patients suffering from atopy: edge of success

The search for new safe and effective methods of immunomodulatory treatment that will prevent the exacerbation of the disease, the development of exacerbations and complications remains a priority task of modern allergology and immunology. This article presents current data on the possibilities of nonspecific immunotropic therapy with the drug Ruzam in the treatment of allergic diseases, including in immunocompromised patients. The drug Ruzam performs endogenous regulation of processes aimed at eliminating immunological dysfunction and suppressing allergic inflammation by influencing cellular and humoral immune responses and nonspecific resistance of the body through the regulation of key cytokines, polarizing the immune response from Th2 to Th1 cells, and reducing the level of IgE in the blood. Due to its universal anti-inflammatory effect, the drug Ruzam has established itself as the first-line drug of choice in patients with AD—the number of exacerbations and their severity decreased during the pollination period of causally significant plants, and the total amount of pharmacological assistance required during the pollen season also decreased. The clinical efficacy of the drug Ruzam in patients with asthma has been confirmed: the intensity and severity of asthma attacks decreased, the amount of drug therapy was reduced by half during treatment, and the duration of remission increased to an average of 2—3 years. The efficacy of Ruzam in AR has been confirmed by its positive therapeutic effect on all major symptoms of AR. The clinical efficacy of Ruzam in patients with AD has been confirmed in studies—compared to placebo, Ruzam significantly reduces the SCORAD index (by 58.93%) and the duration of relapses (by 40%) in patients with mild to moderate AD.